注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Immunome Inc是一家生物制药公司,利用其人类记忆B细胞平台来发现和开发抗体疗法。该公司的主要重点领域是肿瘤学和传染病。其发现平台通过利用免疫系统的组成部分记忆B细胞识别治疗性抗体及其靶点,记忆B细胞来自已经学会对抗疾病的患者。其先导发现项目包括IMM-ONC-01和IMM-BCP-01。该公司的IMM-ONC-01是其主要的肿瘤学项目,专注于白细胞介素38(IL-38),这是一种能够促进免疫系统逃避的肿瘤衍生免疫检查点。IMM-BCP-01是其主要的传染病发现项目,重点关注导致COVID-19的病毒SARS-CoV-2。该公司正在开发一种抗体混合候选产品,方法是确定由COVID-19超级反应者的B细胞产生的抗病毒抗体组合。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Philip Wagenheim | 53 | 2017 | Director |
George C. Prendergast | - | - | Member of Scientific Advisory Board |
Shmuel Shoham | - | 2020 | Member of COVID-19 Advisory Board |
Louis M. Weiner | 72 | - | Member of Scientific Advisory Board |
John M. Lambert | 73 | 2023 | Member of Antibody-Drug Conjugate & T Cell Redirection Advisory Board |
Isaac Barchas | 57 | 2023 | Lead Independent Director |
Jeffrey Henderson | - | 2020 | Member of COVID-19 Advisory Board |
Susan Weiss | - | 2020 | Member of COVID-19 Advisory Board |
Andrew D. Badley | - | 2021 | Member of COVID-19 Advisory Board |
William Strohl | 71 | - | Member of Scientific Advisory Board |
Anthony W. Tolcher | - | - | Member of Scientific Advisory Board and Member of ADC & T Cell Redirection Advisory Board |
Clay B. Siegall | 63 | 2023 | President, CEO & Chairman |
James Patrick Boylan | 56 | 2023 | Independent Director |
Carol A. Schafer | 60 | 2024 | Independent Director |
Sandra M. Swain | 69 | 2024 | Independent Director |
Jean-Jacques Bienaime | 71 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核